TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07914556: A Phase 1, Safety, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy Study of 6MW5311 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients, in Chronic Myelomonocytic Leukemia (CMML) Patients and Multiple

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 122 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07914556 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07914556 Rescue Dossier →